Mouse VEGFR1/Flt-1 Antibody AF471 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemMouse VEGFR1/Flt-1 Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $529.00Supplier Page View Company Product Page
Catalog NumberAF471
NCBI Gene AliasessFlt1, Flt-1, VEGFR1, VEGFR-1
ApplicationsBioassay,ELISA Development,IHC frozen fixed,Flow Cytometry,Immunohistochemistry,Immunoprecipitation,Western Blot,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Neutralization,ELISA Capture (Matched Antibody Pair),Immunocytochemistry,CyTOF-ready
TargetVEGFR1/Flt-1
ReactivityMouse,Rat,Transgenic Mouse
HostGoat
Conjugate/TagUnconjugated
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
IsotypeIgG
Quantity100 ug (also 25 ug)
NCBI Full Gene NameFMS-like tyrosine kinase 1
ClonalityPolyclonal
ImmunogenMouse myeloma cell line NS0-derived recombinant mouse VEGFR1/Flt-1, Ser27-Glu759, Accession # P35969
ConcentrationLYOPH
PurityAntigen Affinity-purified
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Unconjugated

Questions and Answers

Can this antibody be used to study the effects of VEGFR1 in cancer pain models?

Yes, the VEGFR1/Flt-1 Antibody has been utilized in studies investigating cancer pain, where it was shown that blocking VEGFR1 can attenuate tumor-induced nerve remodeling and reduce cancer pain in mouse models. This suggests its potential therapeutic application in managing cancer-associated pain through modulation of VEGFR1 signaling.

Is this antibody effective for immunohistochemistry in mouse tissues?

The VEGFR1/Flt-1 Antibody has been successfully used in immunohistochemistry to detect VEGFR1 expression in various mouse models, including studies on neuroblastoma and muscular dystrophy. It has been cited in multiple publications demonstrating its effectiveness in visualizing VEGFR1 in tissue sections.

How has this antibody been applied in studies related to vascular permeability?

The VEGFR1/Flt-1 Antibody has been employed in research examining the role of Sema3A in increasing vascular permeability during cerebral ischemia. In these studies, the antibody was used to block VEGFR1, which helped elucidate the mechanisms by which Sema3A affects endothelial cell permeability.

What is the significance of using this antibody in studies of angiogenesis?

The VEGFR1/Flt-1 Antibody is significant in angiogenesis research as it has been shown to block the effects of VEGF-B, thereby inhibiting proangiogenic pathways. This has implications for understanding the role of VEGFR1 in tumor angiogenesis and the potential for therapeutic interventions targeting this receptor in cancer treatment.

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Compartmentalized VEGF receptor expression in hypothalamic tanycytes reveals a novel non-endothelial axis of VEGF signaling : Tanycytes as a novel non-endothelial target of VEGF signalingFluids and Barriers of the CNSFebruary 14, 2026Ombeline Desruelle, Manon Leclerc, Sreekala Nampoothiri, Daniela Fernandois, Claude-Alain Maurage, Markus Schwaninger, Vincent Prevot, Ines Martinez-Corralanti-vimentin,[1:4000],AB92547,Abcam Goat anti-collagen IV,[1:500],AB769,Abcam Goat anti-mVEGF R1 (Flt-1),[1:100],AF471,R&D System Goat anti-mVEGF R2 (Flk-1),[1:50],AF644,R&D System Donkey anti-rabbit (488),[1:300],A21206,Invitrogen Donkey

(2) Preventing Differentiation Towards Primitive Macrophages in Stem Cells With Down SyndromeImmunologyNovember 27, 2025Koki Harada, Keiichi Ishihara, Sayaka Wakayama, Teruhiko Wakayama, Sae Yamamoto, Haruhiko Sago, Shun Shimohama, Satoshi Akiba, Florent Ginhoux, Kazuyuki Takatawith primary antibodies: anti‐BMPR1B (1:300, R&D Systems, MAB5051), anti‐VEGFR1 (1:8, R&D Systems, AF471), anti‐VEGFR2 (1:8, R&D Systems, AF644), anti‐VEGFR3 (1:80, R&D Systems, AF743), Mouse IgG2B Isotype

(3) Increased fatty acid delivery by tumor endothelium promotes metastatic outgrowthJCI InsightMay 8, 2025Deanna N. Edwards, Shan Wang, Kelby Kane, Wenqiang Song, Laura C. Kim, Verra M. Ngwa, Yoonha Hwang, Kevin C. Ess, Mark R. Boothby, Jin Chenanimals were treated with 2.5 mg/kg of normal rabbit IgG (R&D Systems, AB-108-C) or αVEGFR1 (R&D Systems, AF471) every 3–4 days by i.p. injection. Lung metastatic tumors were tracked weekly in live animals with bioluminescence

(4) Loss of Bone Morphogenetic Protein-9 Reduces Survival and Increases MMP Activity After Myocardial InfarctionJACC. Basic to translational scienceOctober 1, 2023Bhave S, Esposito M, Swain L, Qiao X, Martin G, Wadhwa S, Everett K, Kapur NK.MMP-9 (AF909; R&D Systems), MMP2 (AF1488; R&D Systems), Flt-1 (Fms related receptor tyrosine kinase 1) (AF471; R&D Systems), vascular endothelial growth factor (VEGF) (NB100-664; Novus), CD-31 (NB 100-2284; Novus),

(5) Beta IV spectrin inhibits the metastatic growth of melanoma by suppressing VEGFR2‐driven tumor angiogenesisCancer MedicineSeptember 7, 2023Eun‐A. Kwak, Tasmia Ahmed, Paola Cruz Flores, Hannah R. Ortiz, Paul R. Langlais, Karthikeyan Mythreye, Nam Y. Lee(#SC514744) and Sigma‐Aldrich (#A1978) respectively. VEGFR1 antibody was purchased from R&D Systems (#AF471). 2.5 Immunohistochemical staining and analysis of B16‐F0 tumors Immunohistochemical (IHC) detection

(6) The VEGF Inhibitor Soluble Fms-like Tyrosine Kinase 1 Does Not Promote AKI-to-CKD TransitionInternational journal of molecular sciencesAugust 26, 2022van Aanhold CCL, Koudijs A, Dijkstra KL, Wolterbeek R, Bruijn JA, van Kooten C, Baelde HJ.against VSV-G (1:2000, V4888, Sigma-Aldrich), luciferase (1:3000, ab181640, Abcam), FLT-1 (1:9000, AF471, R&D Systems) and VCAM-1 (1:800, 553330, BD Biosciences). The appropriate Envision (Dako), Impress (Vector

(7) Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenanceThe Journal of experimental medicineMarch 7, 2022Karaman S, Paavonsalo S, Heinolainen K, Lackman MH, Ranta A, Hemanthakumar KA, Kubota Y, Alitalo K.CAT#IPFL00010), the proteins were detected using goat anti-mouse VEGFR1 (1:1,000; R&D Systems; CAT#AF471), goat anti-mouse VEGFR2 (1:1,000; R&D Systems; CAT#AF644), goat anti-mouse VEGFR3 (1:1,000; R&D Systems;

(8) BMP9 signaling promotes the normalization of tumor blood vesselsOncogeneApril 1, 2020Viallard C, Audiger C, Popovic N, Akla N, Lanthier K, Legault-Navarrete I, Melichar H, Costantino S, Lesage S, Larrivée B.

(9) Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophyPLoS geneticsDecember 1, 2019Verma M, Shimizu-Motohashi Y, Asakura Y, Ennen JP, Bosco J, Zhou Z, Fong GH, Josiah S, Keefe D, Asakura A.anti-FLT1 antibodies were obtained from the manufacturer in carrier free and preservative free form (AF471 from R&D Systems, D2 from Santa Cruz Biotechnology, EWC from Acris GmbH and Novus Biologicals, LS-C6855

(10) Injured Axons Instruct Schwann Cells to Build Constricting Actin Spheres to Accelerate Axonal DisintegrationCell reportsJune 11, 2019Vaquié A, Sauvain A, Duman M, Nocera G, Egger B, Meyenhofer F, Falquet L, Bartesaghi L, Chrast R, Lamy CM, et al.

(11) Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineeringJournal of tissue engineeringJanuary 1, 2019Zhao F, Zhou L, Liu J, Xu Z, Ping W, Li H, Xu L, Xu Z, Zhou C, Wang M, et al.

(12) Mechanistic Insights into the Anti-angiogenic Activity of Trypanosoma cruzi Protein 21 and its Potential Impact on the Onset of Chagasic CardiomyopathyScientific reportsMarch 21, 2017Teixeira SC, Lopes DS, Gimenes SN, Teixeira TL, da Silva MS, Brígido RT, da Luz FA, da Silva AA, Silva MA, Florentino PV, et al.incubated with monoclonal anti-Ezrin (Sigma-Aldrich/E 8897) and VEGFR-1/Flt-1 antibody (R&D Systems/AF471) (gifts from Professor Ricardo José Giordano, Universidade de São Paulo, Brazil) followed by horseradish

(13) PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasiaNature communicationsNovember 29, 2016Ola R, Dubrac A, Han J, Zhang F, Fang JS, Larrivée B, Lee M, Urarte AA, Kraehling JR, Genet G, et al.anti-Eng (AF1320, 1 μg ml−1, R&D systems), anti-Jagged1 (AF599, 1 μg ml−1, R&D systems), anti-Vegfr1 (AF471, 2 μg ml−1, R&D systems), anti-Erg1/2/3 (SC353, 2 μg ml−1, Santa Cruz), anti-α-SMA CY3 (CY3-SMA, C6198,

(14) Negative pressure wound therapy induces early wound healing by increased and accelerated expression of vascular endothelial growth factor receptorsEuropean journal of plastic surgeryJanuary 1, 2016Tanaka T, Panthee N, Itoda Y, Yamauchi N, Fukayama M, Ono M.immunostained with the primary antibodies (goat anti-mouse VEGFR1, VEGFR2, and VEGFR3; R&D Systems catalog nos. AF471, AF644, and AF743, respectively, Minneapolis, MN, USA; 1000-fold dilution) for 16 h at 4 °C within a

(15) A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer PainCancer cellJune 8, 2015Selvaraj D, Gangadharan V, Michalski CW, Kurejova M, Stösser S, Srivastava K, Schweizerhof M, Waltenberger J, Ferrara N, Heppenstall P, et al.injected ipsilaterally intraplantar in the vicinity of the calcaneus bone. Antibodies against VEGFR1 (AF471; R&D Systems), VEGFR2 (AF644; R&D Systems), PLGF-2 (MAB465; R&D Systems), VEGF-B (AF590; R&D Systems),

(16) Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damageScientific reportsJanuary 20, 2015Hou ST, Nilchi L, Li X, Gangaraju S, Jiang SX, Aylsworth A, Monette R, Slinn J.2,Zymed,361500,2 µg (blocking) Anti-Plexin A1,Santa Cruz,sc-25639,2 µg (blocking) Anti-VEGFR1,R&D Systems,AF471,2 µg (blocking) Anti-VEGFR2,R&D Systems,AF644,2 µg (blocking) Anti-hemoglobin subunit alpha,abcam,Ab92492,2

(17) Differential apicobasal VEGF signaling at vascular blood-neural barriersDevelopmental cellSeptember 8, 2014Hudson N, Powner MB, Sarker MH, Burgoyne T, Campbell M, Ockrim ZK, Martinelli R, Futter CE, Grant MB, Fraser PA, et al.then stained as previously described (Slot et al., 1991) using antibodies against VEGFR1 (sc-31173) (AF471; R&D Systems) and VEGFR2 (ab11939) (DC101). Samples were viewed with a JEOL 1010 transmission electron

(18) VEGFR-1 blockade disrupts peri-implantation decidual angiogenesis and macrophage recruitmentVascular cellJanuary 1, 2014Douglas NC, Zimmermann RC, Tan QK, Sullivan-Pyke CS, Sauer MV, Kitajewski JK, Shawber CJ.maintenance of pregnancy in mice. Using two different VEGFR-1 blocking antibodies, MF-1 and R&D Systems AF471 that prevent ligand binding to VEGFR-1, we found that both vascular density and macrophage recruitment

(19) Nonmuscle myosin light-chain kinase mediates microglial migration induced by HIV Tat: involvement of β1 integrinsFASEB journal : official publication of the Federation of American Societies for Experimental BiologyApril 1, 2013Yao H, Duan M, Yang L, Buch S.

(20) Vascular endothelial growth factors A and C are induced in the SVZ following neonatal hypoxia-ischemia and exert different effects on neonatal glial progenitorsTranslational stroke researchApril 1, 2013Bain JM, Moore L, Ren Z, Simonishvili S, Levison SW.incubated with VEGF-C (Cys156Ser) (R&D Systems; 100ng/ml) and blocking antibodies to either VEGFR-1 (cat #AF471, R&D Systems, 5µg/ml), or VEGFR-2 (cat #AF644, R&D Systems, 0.2 µg/ml), or VEGFR-3 (ImClone IMC-3C5,

Be the First to Write a Review!

VEGFR1/Flt-1 Antibody

VEGFR1/Flt-1 Antibody

Mouse VEGFR1/Flt-1 Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

Questions and Answers

R&D Systems, a Bio-Techne Brand

Citations (46)

Reviews

Mouse VEGFR1/Flt-1 Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map